Antidepressants trigger opposite reactions in different groups of serotonin-producing brain cells
Selective serotonin reuptake inhibitors (SSRIs) are among the world’s most common antidepressants, yet their exact mechanism of action has long remained a mystery. A recent study published in Molecular Psychiatry reveals that these drugs trigger opposite effects in different serotonin-producing brain cells, potentially explaining why patients often experience initial side effects before feeling therapeutic relief.
Did You Know? In Sweden, the prevalence of antidepressant use is significant, with more than one in ten people currently taking these medications, making SSRIs the most common treatment option.
How SSRIs affect the brain
Researchers focused on the Dorsal Raphe Nucleus, the brain’s primary region for producing serotonin. By utilizing a high-resolution technique known as spatial transcriptomics, the team mapped how fluoxetine—a widely prescribed SSRI—alters gene activity. According to Iskra Pollak Dorocic, Assistant Professor at Stockholm University, the serotonin system is not a uniform population of cells, but rather a diverse group of neurons that respond to medication in distinct ways.
Why the treatment timeline varies
The study identified two specific subpopulations of serotonin neurons that respond to SSRIs at different stages of treatment. One group increases the expression of prodynorphin (Pdyn) shortly after beginning the medication. Since Pdyn signaling is associated with stress-induced depressive symptoms, this spike may explain the anxiety or mood worsening some patients report during the first days of treatment.
Conversely, a second population of neurons begins to express thyrotropin-releasing hormone (TRH) only after prolonged exposure. Because TRH is linked to anti-depressive functions, this delayed reaction likely accounts for the therapeutic benefits that typically emerge after several weeks of consistent use.
Expert Insight: The transition from Pdyn-driven side effects to TRH-driven relief suggests that the “lag time” patients experience when starting SSRIs is not merely a clinical observation, but a reflection of competing molecular pathways within the brain. Understanding this shift could be the key to managing patient expectations and potentially developing treatments that bypass the initial, uncomfortable phase.
Future directions for antidepressant research
These findings provide concrete molecular targets for researchers aiming to refine psychiatric care. By identifying the specific pathways that govern both the negative and positive responses to SSRIs, scientists may be able to develop more targeted medications. Future research could focus on modulating these specific neuron populations to minimize side effects while maintaining or accelerating the therapeutic impact of the drug.
Frequently Asked Questions
Why do some patients feel worse before they feel better on SSRIs?
The study suggests that short-term SSRI use increases the expression of the neuropeptide prodynorphin in specific serotonin neurons, which is linked to stress-induced depressive symptoms and may cause increased anxiety or worsening mood.
What role does TRH play in antidepressant treatment?
Thyrotropin-releasing hormone (TRH) expression increases in a specific subpopulation of serotonin neurons after prolonged SSRI treatment, which researchers associate with the therapeutic, anti-depressive effects of the medication.
How did the researchers distinguish between different serotonin neurons?
The team used a technique called spatial transcriptomics to read gene activity at high resolution, allowing them to map different types of serotonin neurons within the Dorsal Raphe Nucleus rather than treating them as a single, uniform population.
How do you believe understanding the biological timeline of medication side effects might change the way doctors discuss treatment plans with their patients?